[go: up one dir, main page]

PT3840767T - Peptídeos - Google Patents

Peptídeos

Info

Publication number
PT3840767T
PT3840767T PT207284977T PT20728497T PT3840767T PT 3840767 T PT3840767 T PT 3840767T PT 207284977 T PT207284977 T PT 207284977T PT 20728497 T PT20728497 T PT 20728497T PT 3840767 T PT3840767 T PT 3840767T
Authority
PT
Portugal
Prior art keywords
peptides
Prior art date
Application number
PT207284977T
Other languages
English (en)
Original Assignee
Hubro Therapeutics As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hubro Therapeutics As filed Critical Hubro Therapeutics As
Publication of PT3840767T publication Critical patent/PT3840767T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT207284977T 2019-05-29 2020-05-28 Peptídeos PT3840767T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19177444 2019-05-29

Publications (1)

Publication Number Publication Date
PT3840767T true PT3840767T (pt) 2024-01-29

Family

ID=66677029

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207284977T PT3840767T (pt) 2019-05-29 2020-05-28 Peptídeos

Country Status (22)

Country Link
US (1) US20220213170A1 (pt)
EP (2) EP3840767B1 (pt)
JP (2) JP2022535784A (pt)
KR (1) KR20220012938A (pt)
CN (1) CN113891723A (pt)
AU (1) AU2020281912A1 (pt)
BR (1) BR112021023957A2 (pt)
CA (1) CA3141951A1 (pt)
CO (1) CO2021017664A2 (pt)
DK (1) DK3840767T5 (pt)
ES (1) ES2970223T3 (pt)
FI (1) FI3840767T3 (pt)
HR (1) HRP20240017T1 (pt)
HU (1) HUE065269T2 (pt)
IL (1) IL288412A (pt)
LT (1) LT3840767T (pt)
MX (1) MX2021014497A (pt)
PL (1) PL3840767T3 (pt)
PT (1) PT3840767T (pt)
SG (1) SG11202113125QA (pt)
SI (1) SI3840767T1 (pt)
WO (1) WO2020239937A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230203130A1 (en) 2020-05-28 2023-06-29 Hubro Therapeutics As A peptide cocktail
MX2024000448A (es) 2021-07-09 2024-01-29 Hubro Therapeutics As Cebador.
EP4223782A1 (en) * 2022-02-07 2023-08-09 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Novel t cell receptors and immune therapy using the same for the treatment of cancer
WO2024052542A2 (en) 2022-09-09 2024-03-14 Hubro Therapeutics As A peptide cocktail
WO2024149791A1 (en) 2023-01-11 2024-07-18 Hubro Therapeutics As A primer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US8053552B2 (en) * 2002-04-18 2011-11-08 Mtm Laboratories, Ag Neopeptides and methods useful for detection and treatment of cancer
DK1764372T3 (da) * 2005-09-20 2009-11-30 Peter Jon Nelson Vævsinhibitor af metalloproteinaser (TIMP) bundet til glycosylphosphatidylinositol (GPI)-ankre til behandling af cancer
JP2013523084A (ja) * 2010-04-09 2013-06-17 オンコセラピー・サイエンス株式会社 Cdca5ペプチドおよびそれを含むワクチン
CA2798988C (en) * 2010-05-17 2020-03-10 Sangamo Biosciences, Inc. Tal-effector (tale) dna-binding polypeptides and uses thereof
JP2016028025A (ja) * 2015-07-29 2016-02-25 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクRuprecht−Karls−Universitaet Heidelberg がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp)
US20200188496A1 (en) * 2017-06-02 2020-06-18 Arizona Board Of Regents On Behalf Of Arizona State University Universal cancer vaccines and methods of making and using same

Also Published As

Publication number Publication date
BR112021023957A2 (pt) 2022-02-01
CO2021017664A2 (es) 2022-01-17
JP2025066801A (ja) 2025-04-23
EP3840767B1 (en) 2023-11-15
AU2020281912A1 (en) 2022-01-20
DK3840767T5 (da) 2024-08-19
PL3840767T3 (pl) 2024-03-04
IL288412A (en) 2022-01-01
ES2970223T3 (es) 2024-05-27
FI3840767T3 (fi) 2024-01-31
DK3840767T3 (da) 2024-02-12
EP3840767A1 (en) 2021-06-30
HRP20240017T1 (hr) 2024-04-26
CN113891723A (zh) 2022-01-04
SI3840767T1 (sl) 2024-04-30
US20220213170A1 (en) 2022-07-07
WO2020239937A1 (en) 2020-12-03
MX2021014497A (es) 2022-02-11
JP2022535784A (ja) 2022-08-10
KR20220012938A (ko) 2022-02-04
CA3141951A1 (en) 2020-12-03
LT3840767T (lt) 2024-02-26
EP4276463A2 (en) 2023-11-15
EP4276463A3 (en) 2024-01-10
HUE065269T2 (hu) 2024-05-28
SG11202113125QA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
IL289122A (en) polypeptides
IL275298B1 (en) Mitochondria-targeted peptides
IL288412A (en) peptides
IL289119A (en) polypeptides
IL318744A (en) Cell-penetrating peptides
GB201700557D0 (en) Novel peptides
IL290520A (en) Medicinal peptides
SG11202005653RA (en) Novel peptide
IL285144A (en) Medicinal peptides
GB201812980D0 (en) Cell-penetrating peptides
GB201810052D0 (en) Polypeptide
IL290019A (en) Peptides to regulate melanocytes
GB201900443D0 (en) Cell-penetrating peptides
GB201906982D0 (en) Peptides
GB201902850D0 (en) Antimicroial peptides
GB201918693D0 (en) Peptide
GB201912632D0 (en) Peptide
GB202113858D0 (en) Peptides
GB202110693D0 (en) Peptides
GB201807863D0 (en) Peptides
GB201806181D0 (en) Peptides
GB201805807D0 (en) Peptides
GB201805801D0 (en) Peptides
GB201805809D0 (en) Peptides
GB201814440D0 (en) Peptide